Drugs / Fluorothiazinone
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07184606 | Sep → Dec 2025 overdue | — | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06135350 | Nov 2023 → Dec 2025 overdue | pneumonia caused by gram negative bacteria | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06815549 | Feb → Dec 2025 overdue | Enterococcus faecalis infection, Klebsiella pneumonia, Pseudomonas aeruginosa infectious disease, chronic cystitis +1 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluorothiazinone | “Clinical Study of the Safety and Pharmacokinetics of the Drug Fluorothiazinone, a Concentrate for Solution Preparation for Infusion.” NCT07184606 ↗ |
| Route | Other | “parenteral administration” NCT07184606 ↗ |